Randomized controlled trialHuman
Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2021 Nov. Mahlapuu M, Sidorowicz A, Mikosinski J and 17 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Published
2021 Nov
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AgedDouble-Blind MethodHumansLeg UlcerProspective StudiesTreatment OutcomeVaricose UlcerWound Healing
Other papers on LL-37
Randomized controlled trial · 2014
Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Review · 2016LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
Journal article · 2006The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page